KR20250089513A - 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용 - Google Patents

암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용 Download PDF

Info

Publication number
KR20250089513A
KR20250089513A KR1020257015107A KR20257015107A KR20250089513A KR 20250089513 A KR20250089513 A KR 20250089513A KR 1020257015107 A KR1020257015107 A KR 1020257015107A KR 20257015107 A KR20257015107 A KR 20257015107A KR 20250089513 A KR20250089513 A KR 20250089513A
Authority
KR
South Korea
Prior art keywords
cldn4
antibody
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257015107A
Other languages
English (en)
Korean (ko)
Inventor
마사히토 사토
게이타 히로우치
아야 기쿠치
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20250089513A publication Critical patent/KR20250089513A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257015107A 2022-10-19 2023-10-18 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용 Pending KR20250089513A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022167362 2022-10-19
JPJP-P-2022-167362 2022-10-19
PCT/JP2023/037616 WO2024085166A1 (ja) 2022-10-19 2023-10-18 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Publications (1)

Publication Number Publication Date
KR20250089513A true KR20250089513A (ko) 2025-06-18

Family

ID=90737914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257015107A Pending KR20250089513A (ko) 2022-10-19 2023-10-18 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용

Country Status (10)

Country Link
EP (1) EP4606384A1 (https=)
JP (1) JP7730432B2 (https=)
KR (1) KR20250089513A (https=)
CN (1) CN119997975A (https=)
AU (1) AU2023365438A1 (https=)
CL (1) CL2025001156A1 (https=)
IL (1) IL319946A (https=)
MX (1) MX2025004457A (https=)
TW (1) TW202426503A (https=)
WO (1) WO2024085166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2016177802A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP3445788B1 (en) * 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
AU2022262542A1 (en) * 2021-04-22 2023-11-02 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
WO2016177802A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
Annual Review of Immunology, 2008: Vol. 26: p. 677-704
Cancer Discovery, 2021: 11: p. 1368-1397
Cancer Immunology Immunotherapy, 2012: 61(5): p. 1721-1733
Cancer Science, 2009: 100(9): p. 1623-1630
Cancer Science, 2020: 111(5): p. 1461-1467
Clinical Cancer Research, 2017: 23(8): p. 1929-1936
Clinical Cancer Research, 2019: 25(19): p. 5878-5889
Clinical Cancer Research, 2020: 26(15): p. 4154-4167
International Immunology, 1996: Vol. 8: p. 765-772
Journal for Immunotherapy of Cancer, 2019: 7: 37: p. 1-16
Journal for Immunotherapy of Cancer, 2020: 8(2): e000238
MAbs, 2017: 9(2): p. 182-212
Molecular Medicine Reports, 2021: 23: p. 362-377
Molecules, 2019: 24: p. 2071-2100
Nature Communications, 2017: 8: p. 14572-14582
Nature Medicine, 2002: 8: p. 793-800
Oncotarget, 2018: 9(100): p. 37367-37378
Scientific Reports, 2021: 11: p. 21087-21099

Also Published As

Publication number Publication date
MX2025004457A (es) 2025-05-02
IL319946A (en) 2025-05-01
CL2025001156A1 (es) 2025-05-23
AU2023365438A1 (en) 2025-04-17
EP4606384A1 (en) 2025-08-27
JP7730432B2 (ja) 2025-08-27
JPWO2024085166A1 (https=) 2024-04-25
WO2024085166A1 (ja) 2024-04-25
TW202426503A (zh) 2024-07-01
CN119997975A (zh) 2025-05-13

Similar Documents

Publication Publication Date Title
CN113166262B (zh) Pd-1单结构域抗体及其治疗组合物
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
AU2018393424B2 (en) Triabody, preparation method and use thereof
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
CN111094350B (zh) 调节由细胞表达的生物活性的抗体
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
RS53072B (sr) Antitela za humani receptor programirane smrti pd-1
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
US12312409B2 (en) Bispecific CD137-binding antibodies for T-cell activation
CN114790241B (zh) 抗tigit抗体及其应用
EP4480966A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
JP7730432B2 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
WO2024173376A2 (en) Combination therapy comprising multispecific gamma delta tcr antibodies
HK40127540A (en) Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment
EA052933B1 (ru) Применение биспецифического антитела против cldn4/против cd137 в комбинации с ингибитором сигнала pd-1 для лечения злокачественной опухоли
JP2025087939A (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
EP4682170A1 (en) Novel cd3-binding antibody and multispecific antibody comprising same
EP4524248A1 (en) Anti-taa/anti-cd3 multispecific antibody
TW202544034A (zh) 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
KR20240161968A (ko) 다중 특이적 분자와 면역 체크 포인트 저해제의 조합
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
WO2026042803A1 (ja) がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
JP2026508096A (ja) 治療抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501